Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant

NCT02490202 is registered in ClinicalTrials.gov with Prolong Pharmaceuticals as lead sponsor.

NCT NCT02490202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02490202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant
Lead sponsor
Prolong Pharmaceuticals
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2015
Completion date
October 31, 2016
Enrollment
60 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

delayed function of renal transplant